WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD)
today announced it has appointed Michael Pollock vice president of real
world outcomes. Pollock is responsible for directing and enhancing PPD’s
capabilities in health outcomes and evidence-based medicine to help
biopharmaceutical clients optimize market and patient access to novel
therapies.

“PPD is continually strengthening its offerings across the real world
outcomes spectrum, and Michael brings a unique background to this role,
having held senior positions both in sales and marketing, and in health
economics for both large pharmaceutical and biotechnology companies,”
said Rob Dow, M.D., PPD’s senior vice president of medical affairs. “He
has the knowledge, experience and leadership skills to help grow PPD’s
real world outcomes solutions, as we drive value and fuel success for
clients.”

Most recently, Pollock was president of Reynolds Pollock & Associates, a
health outcomes research and market access strategy consulting company.
Previous biopharmaceutical industry roles include: vice president of
global health economics at Biogen Idec; vice president of sales and
marketing at Elan Pharmaceuticals; vice president of sales and marketing
and information services at Oncology Therapeutics Network, a division of
Bristol-Myers Squibb; and director and head of worldwide health
economics at Glaxo Wellcome (now GlaxoSmithKline).

Pollock earned a bachelor’s degree in applied biology from the
University of Ulster in Northern Ireland and completed graduate work in
marketing at the College of Marketing and Design in Dublin, Ireland. An
adjunct professor at the Rady School of Management at the University of
California, San Diego, he teaches courses on health economics and the
biotechnology industry.

About PPD

PPD is a leading global contract
research organization providing drug
discovery, development, lifecycle management and laboratory
services. Our clients and partners include pharmaceutical,
biotechnology,
medical
device, academic and government
organizations. With offices in 46 countries and more than 13,000
professionals worldwide, PPD applies innovative technologies,
therapeutic expertise and a commitment to quality to help clients and
partners accelerate the delivery of safe and effective therapeutics and
maximize the returns on their R&D investments. For more information,
visit www.ppdi.com.

Except for historical information, all of the statements,
expectations and assumptions, including statements, expectations and
assumptions about PPD’s real world outcomes services, contained in this
news release are forward-looking statements that involve a number of
risks and uncertainties. Although PPD attempts to be accurate in making
these forward-looking statements, it is possible that future
circumstances might differ from the assumptions on which such statements
are based and could cause actual results to differ materially from the
forward-looking statements. Other important factors that could cause
future results to differ materially include the following: the ability
to attract, integrate, retain and train key personnel; competition in
the outsourcing industry; rapid technological advances that make our
services or capabilities less competitive; compliance with drug
development regulations; changes in the regulation of the drug
development process; PPD’s ability to win new business; overall global
economic conditions; economic conditions, research and development
spending, and outsourcing trends in the pharmaceutical, biotechnology
and government-sponsored research sectors; consolidation in the
pharmaceutical and biotechnology industries; loss, delay or modification
of large contracts; higher-than-expected cancellation rates; the rate of
conversion of backlog into revenue; risks associated with and dependence
on strategic relationships; actual operating performance; risks
associated with acquisitions and investments; and the ability to control
SG&A spending. PPD assumes no obligation and expressly disclaims any
duty to update these forward-looking statements in the future, except as
required by applicable law. These forward-looking statements should not
be relied upon as representing PPD’s estimates or views as of any date
subsequent to the date hereof.